Key facts
- This page summarizes Michael J. Kaufman's Form 4 filing for Mersana Therapeutics, Inc. (MRSN).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Jul 2021, 20:50.
Michael J. Kaufman - 15 Jul 2021 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)
- Reporting relationship
- Chief Manufacturing Officer
- Issuer ticker
- MRSN
- Reported as of
- 15 Jul 2021
- Net transaction value
- -$147,897
- Reporting owner signature
- /s/ Brian DeSchuytner, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Michael J. Kaufman filed Form 4 for Mersana Therapeutics, Inc. (MRSN) on 19 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$147,897.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRSN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +40,000
- Change %
- +849%
- Price
- Shares after
- 44,710
- Date
- 15 Jul 2021
- Ownership
- Direct
- Footnotes
- F1
MRSN
transaction
Common Stock
Sale
- Transaction value
- $72,027
- Shares
- -5,776
- Change %
- -13%
- Price
- $12.47*
- Shares after
- 38,934
- Date
- 16 Jul 2021
- Ownership
- Direct
- Footnotes
- F2, F3
MRSN
transaction
Common Stock
Sale
- Transaction value
- $75,870
- Shares
- -6,312
- Change %
- -16%
- Price
- $12.02*
- Shares after
- 32,622
- Date
- 19 Jul 2021
- Ownership
- Direct
- Footnotes
- F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRSN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -40,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each restricted stock unit ("RSU") listed in Table II represented a contingent right to receive one share of the Issuer's common stock upon vesting.
Footnote F2
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy her tax withholding obligations and does not represent a discretionary trade by the reporting person
Footnote F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.27 to $12.61, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Footnote F4
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.90 to $12.23, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
Footnote F5
The RSUs vested in their entirety on July 15, 2021.